Table 1.
Characteristics of the patients
| Characteristic | Total (n = 38) |
|---|---|
| Age (years) | 59.4 ± 9.2 |
| Median (range) | 60 (35, 79) |
| Sex, n (%) | |
| Male | 32 (84.2) |
| Female | 6 (15.8) |
| ECOG performance status, n (%) | |
| 0 | 20 (52.6) |
| 1 | 13 (34.2) |
| 2 | 5 (13.2) |
| BCLC grade, n (%) | |
| B | 18 (47.4) |
| C | 20 (52.6) |
| Hepatitis, n (%) | |
| Hepatitis B | 32 (84.2) |
| Hepatitis C | 2 (5.3) |
| No | 4 (10.5) |
| Maximum tumor size (cm) | 3.75 (0.9, 15.1) |
| Tumor number, n (%) | |
| Single | 4 (10.5) |
| Multiple | 32 (84.2) |
| Unknown | 2 (5.3) |
| Child–Pugh grade, n (%) | |
| A | 37 (97.4) |
| B | 1 (2.6) |
| Macrovascular invasion, n (%) | 12 (31.6) |
| AFP ≥ 400 μg/L, n (%) | 11 (28.9) |
| Comorbidity, n (%) | |
| Hypertension | 15 (39.5) |
| Diabetes Mellitus | 4 (10.5) |
| Extrahepatic metastasis, n (%) | 13 (34.2) |
| Prior local therapy, n (%) | |
| Surgery | 13 (34.2) |
| Ablation | 20 (52.6) |
| TACE | 36 (94.7) |
| Radiotherapy | 6 (15.8) |
| Prior systemic therapy, n (%) | |
| Sorafenib | 33 (86.8) |
| Lenvatinib | 1 (2.6) |
| Lenvatinib sequential to sorafenib | 4 (10.5) |
| Follow-up (months), median (range) | 5.6 (0.7, 17.0) |
ECOG Eastern Cooperative Oncology Group, BCLC Barcelona clinic liver cancer, AFP α-fetoprotein, TACE transarterial chemoembolization